CUE-102

BIOLOGICAL2 trials

Sponsors

Cue Biopharma, David Reardon, MD

Conditions

Colorectal CancerGastric CancerGlioblastomaGlioma, MalignantOvarian CancerPancreatic CancerRecurrent Glioblastoma

Phase 1

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

CompletedNCT05360680

Cue BiopharmaColorectal Cancer, Gastric Cancer, Ovarian Cancer +1

Start: 2022-06-14End: 2025-03-12Updated: 2026-01-22

CUE-102 in Recurrent Glioblastoma

RecruitingNCT06917885

David Reardon, MDGlioblastoma, Glioma, Malignant, Recurrent Glioblastoma

Start: 2025-07-30End: 2028-01-31Target: 18Updated: 2026-03-05

Related Papers

A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.

Journal of Clinical Oncology2024-06-01

750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

Regular and Young Investigator Award Abstracts2023-10-31

636 A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

Regular and Young Investigator Award Abstracts2022-11-01

1323 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

Regular and Young Investigator Award Abstracts2022-11-01